Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADGINASDAQ:APGENASDAQ:CGONNASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADGIAdagio Therapeutics$4.21$2.41▼$78.82$504.98MN/A2.27 million shs22,357 shsAPGEApogee Therapeutics$44.48+6.3%$37.29$26.20▼$63.50$2.05B1.38553,734 shs1.25 million shsCGONCG Oncology$25.86-2.4%$24.04$14.80▼$40.47$1.97B0.86837,930 shs626,383 shsIMCRImmunocore$34.68-2.7%$31.06$23.15▼$41.54$1.74B0.83362,037 shs435,478 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADGIAdagio Therapeutics0.00%0.00%0.00%0.00%0.00%APGEApogee Therapeutics0.00%+8.54%+9.45%+11.37%+0.38%CGONCG Oncology0.00%-3.90%+2.01%-6.98%-27.18%IMCRImmunocore0.00%-6.90%+19.34%+20.42%-14.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADGIAdagio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPGEApogee Therapeutics2.3948 of 5 stars3.51.00.00.02.44.20.0CGONCG Oncology2.4409 of 5 stars4.51.00.00.02.90.80.0IMCRImmunocore3.0455 of 5 stars4.30.00.00.03.44.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADGIAdagio Therapeutics 0.00N/AN/AN/AAPGEApogee Therapeutics 3.00Buy$94.60112.68% UpsideCGONCG Oncology 3.00Buy$58.22125.14% UpsideIMCRImmunocore 2.55Moderate Buy$58.8969.81% UpsideCurrent Analyst Ratings BreakdownLatest ADGI, CGON, APGE, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/2/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.004/29/2025CGONCG OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.004/28/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$75.00 ➝ $75.004/28/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.004/16/2025CGONCG OncologyScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$23.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADGIAdagio TherapeuticsN/AN/AN/AN/A$5.02 per shareN/AAPGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/ACGONCG Oncology$662K2,977.61N/AN/A($1.94) per share-13.33IMCRImmunocore$333.58M5.22N/AN/A$7.42 per share4.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADGIAdagio Therapeutics-$226.79M-$3.15N/AN/AN/AN/A-57.14%-50.28%N/AAPGEApogee Therapeutics-$83.99M-$3.60N/AN/AN/AN/A-21.81%-20.94%8/11/2025 (Estimated)CGONCG Oncology-$48.61M-$1.51N/AN/AN/A-10,642.98%-18.97%-15.36%8/14/2025 (Estimated)IMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/6/2025 (Estimated)Latest ADGI, CGON, APGE, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADGIAdagio TherapeuticsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADGIAdagio TherapeuticsN/A7.097.09APGEApogee TherapeuticsN/A16.3916.39CGONCG OncologyN/A35.3235.32IMCRImmunocore1.033.783.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADGIAdagio Therapeutics96.94%APGEApogee Therapeutics79.04%CGONCG Oncology26.56%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipADGIAdagio TherapeuticsN/AAPGEApogee Therapeutics42.77%CGONCG Oncology7.40%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADGIAdagio Therapeutics2,021108.83 millionN/ANot OptionableAPGEApogee Therapeutics9146.05 million28.77 millionOptionableCGONCG Oncology6176.23 millionN/AOptionableIMCRImmunocore32050.23 million45.48 millionOptionableADGI, CGON, APGE, and IMCR HeadlinesRecent News About These CompaniesImmunocore (NASDAQ:IMCR) Upgraded by Wall Street Zen to "Buy" RatingJune 15 at 3:43 AM | americanbankingnews.comImmunocore (NASDAQ:IMCR) Rating Increased to Buy at Wall Street ZenJune 14 at 2:10 AM | marketbeat.comCantor Fitzgerald Comments on Immunocore FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates Immunocore FY2026 EarningsJune 10, 2025 | marketbeat.comGAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)June 10, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Shares Down 4.5% - What's Next?June 9, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Rating Lowered by Wall Street ZenJune 9, 2025 | americanbankingnews.comWall Street Zen Downgrades Immunocore (NASDAQ:IMCR) to HoldJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Grows Position in Immunocore Holdings plc (NASDAQ:IMCR)June 6, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Given "Buy" Rating at HC WainwrightJune 2, 2025 | marketbeat.comWall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a BetJune 2, 2025 | zacks.comImmunocore to present at the 2025 Jefferies Global Healthcare ConferenceJune 2, 2025 | globenewswire.comImmunocore (NASDAQ:IMCR) Trading Up 6.3% - Here's WhyMay 30, 2025 | marketbeat.comBank of America Corp DE Sells 95,362 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 29, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Shares Gap Up - What's Next?May 28, 2025 | marketbeat.comDeutsche Bank Aktiengesellschaft Begins Coverage on Immunocore (NASDAQ:IMCR)May 28, 2025 | marketbeat.comJefferies Financial Group Inc. Buys New Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 28, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 26, 2025 | marketbeat.comWoodline Partners LP Has $9.68 Million Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)May 25, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Position Trimmed by Two Sigma Advisers LPMay 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADGI, CGON, APGE, and IMCR Company DescriptionsAdagio Therapeutics NASDAQ:ADGIAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Apogee Therapeutics NASDAQ:APGE$44.48 +2.62 (+6.26%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$44.11 -0.37 (-0.83%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.CG Oncology NASDAQ:CGON$25.86 -0.64 (-2.42%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$26.92 +1.06 (+4.11%) As of 06/13/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Immunocore NASDAQ:IMCR$34.68 -0.95 (-2.67%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.63 -0.05 (-0.14%) As of 06/13/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
